HeartFlow Inc. logo

HeartFlow Inc. (HTFL)

Market Open
26 Oct, 05:38 PM
NASDAQ (NMS) NASDAQ (NMS)
$
56. 60
-0.11
-0.1936%
$
4.93B Market Cap
- P/E Ratio
- Div Yield
387,690 Volume
- Eps
$ 56.71
Previous Close
Add Transaction
Day Range
56.32 57.55
Year Range
20.13 57.74
Want to track HTFL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

HTFL trading today lower at $56.6, a decrease of -0.1936% from yesterday's close, completing a monthly increase of 13.6322% or $6.79. Over the past 12 months, HTFL stock gained 92.8457%.
HTFL is not paying dividends to its shareholders.
The last earnings report, released on Mar 18, 2026, exceeded the consensus estimates by 0.1683%. On average, the company has surpassed earnings expectations by 0.1694%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

HTFL Chart

People also search for

Kymera Therapeutics Inc.
$ 114.5
+3.3772%
Protagonist Therapeutics, Inc.
$ 140.97
+1.8366%
Abivax SA Sponsored ADR
$ 86.67
-1.5226%
Axsome Therapeutics Inc.
$ 143.84
-0.8274%
Iovance Biotherapeutics Inc.
$ 13.76
-2.3691%
HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High

HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High

The sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85. The traded shares represent 13% of the equity stake held by the officer before the transaction.

Fool | 1 month ago
HeartFlow: An Impressive MedTech Growth Play

HeartFlow: An Impressive MedTech Growth Play

HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution.

Seekingalpha | 2 months ago
HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript

HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript

HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 months ago

HeartFlow Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Curtis Ellergodt
Curtis Ellergodt Rothschild Investment LLC
222 $6,012.22 $12,356.52 $6,344.3 105.52%
BG
Bart Gancher Intech Investment Management LLC
16,384 $480,706.56 $912,274.23 $431,567.67 89.78%
GN
Gina Nelson Next Century Growth Investors LLC
671,404 $16.43M $37.36M $20.93M 127.43%
KM
Kristin Mariani Janus Henderson Group PLC
865,560 $29.13M $49.34M $20.2M 69.34%
MM
Mike Muhizi SG Americas Securities LLC
7,420 $216,056 $421,530.2 $205,474.2 95.1%

HeartFlow Inc. Analysts

Name Quantity Cost Value Profit ($) Gain (%)
MO
Matt OBrien Piper Sandler
2,488.42 $104,712.78 $142,263.06 $37,550.28 35.86%

HeartFlow Inc. (HTFL) FAQ

What is the stock price today?

The current price is $56.60.

On which exchange is it traded?

HeartFlow Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is HTFL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 4.93B.

Has HeartFlow Inc. ever had a stock split?

No, there has never been a stock split.

HeartFlow Inc. Profile

Health Care Technology Industry
Healthcare Sector
John Farquhar CEO
NASDAQ (NMS) Exchange
42238D107 CUSIP
US Country
843 Employees
- Last Dividend
- Last Split
- IPO Date
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Contact Information

Address: 135 Main Street
Phone: 650-241-1221